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Background: Antifolates are currently in clinical use for malaria preventive therapy and treatment. The drugs kill
the parasites by targeting the enzymes in the de novo folate pathway. The use of antifolates has now been limited
by the spread of drug-resistant mutations. GTP cyclohydrolase I (GCH1) is the first and the rate-limiting enzyme in
the folate pathway. The amplification of the gch1 gene found in certain Plasmodium falciparum isolates can cause
antifolate resistance and influence the course of antifolate resistance evolution. These findings showed the
importance of P. falciparum GCH1 in drug resistance intervention. However, little is known about P. falciparum
GCH1 in terms of kinetic parameters and functional assays, precluding the opportunity to obtain the key
information on its catalytic reaction and to eventually develop this enzyme as a drug target.
Methods: Plasmodium falciparum GCH1 was cloned and expressed in bacteria. Enzymatic activity was determined
by the measurement of fluorescent converted neopterin with assay validation by using mutant and GTP analogue.
The genetic complementation study was performed in ΔfolE bacteria to functionally identify the residues and
domains of P. falciparum GCH1 required for its enzymatic activity. Plasmodial GCH1 sequences were aligned and
structurally modeled to reveal conserved catalytic residues.
Results: Kinetic parameters and optimal conditions for enzymatic reactions were determined by the fluorescence-based
assay. The inhibitor test against P. falciparum GCH1 is now possible as indicated by the inhibitory effect by 8-oxo-GTP.
Genetic complementation was proven to be a convenient method to study the function of P. falciparum GCH1. A series
of domain truncations revealed that the conserved core domain of GCH1 is responsible for its enzymatic activity.
Homology modelling fits P. falciparum GCH1 into the classic Tunnelling-fold structure with well-conserved catalytic
residues at the active site.
Conclusions: Functional assays for P. falciparum GCH1 based on enzymatic activity and genetic complementation were
successfully developed. The assays in combination with a homology model characterized the enzymatic activity of P.
falciparum GCH1 and the importance of its key amino acid residues. The potential to use the assay for inhibitor screening
was validated by 8-oxo-GTP, a known GTP analogue inhibitor.
Keywords: Antifolate, Folate pathway, GTP cyclohydrolase I, Malaria* Correspondence: thanat.cho@mahidol.edu
†Equal contributors
1Department of Biochemistry, Faculty of Science, Mahidol University, Bangkok
10400, Thailand
3Center of Excellence in Malaria, Faculty of Tropical Medicine, Mahidol
University, Bangkok 10400, Thailand
Full list of author information is available at the end of the article
© 2014 Kümpornsin et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the
Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly credited.
Kümpornsin et al. Malaria Journal 2014, 13:150 Page 2 of 11
http://www.malariajournal.com/content/13/1/150Background
The folate pathway of Plasmodium falciparum is a well-
established malaria drug target with proven benefits in
treatment and prophylaxis [1,2]. The combination of antifo-
late pyrimethamine and sulphadoxine has been included in
anti-malarial drug regimens for decades [3]. These antifo-
late compounds target two different enzymes in the folate
pathway of P. falciparum, with pyrimethamine and sulpha-
doxine inhibiting dihydrofolate reductase (DHFR) and
dihydropteroate synthase (DHPS), respectively [3]. The in-
hibition of the folate pathway cuts down the amount of fol-
ate derivatives that act as one-carbon carriers in nucleotide
synthesis and amino acid metabolism. The malaria parasites
became resistant to antifolates by gaining mutations at the
dhfr and dhps genes [4-6]. The residue changes decrease
the binding affinity of the drugs to the targeted enzymes
[7,8]. The interest in antifolates has been renewed in recent
years with the development of new lead compounds and
the novel applications in malaria treatment [3,9]. Next-
generation antifolates have now been developed in order to
target drug-resistant folate enzymes [10]. The new P218
compound was designed to fit into the active site of
pyrimethamine-resistant DHFR resulting in effective clear-
ance of drug-resistant parasites [11]. Moreover, the existing
antifolates can save the lives of infants and pregnant
women at risk from malaria when administered as intermit-
tent preventive regimens [9,12-14].
The rise in genomic analyses of malaria parasites re-
vealed a unique role of GTP cyclohydrolase I (GCH1),
the first and the rate-limiting enzyme of the folate path-
way, in pyrimethamine resistance (Figure 1) [15]. Copy
number polymorphism of P. falciparum gch1 is found in
malaria parasites from certain endemic countries, with
some isolates from Thailand containing more than ten
copies of gch1 [16,17]. Extra P. falciparum GCH1 from
gene amplification was shown to reduce pyrimethamine
sensitivity slightly, but, most important of all, the extra
enzyme could reduce the cost of drug-resistant muta-
tions to the parasite during the gain of pyrimethamine
resistance [18,19]. The increase in the rate-limiting
GCH1 was found to improve the folate flux by several
orders of magnitude [20]. The drug-resistant mutations
at dhfr, though advantageous under pyrimethamine pres-
sure, are costly in terms of fitness due to the changes at
the active site [21-23]. Having extra rate-limiting GCH1
can boost the folate flux to compensate for the loss of
the products in the pathway. The role of P. falciparum
GCH1 in drug resistance evolution makes it necessary to
characterize this enzyme biochemically and functionally.
Understanding the properties of P. falciparum GCH1
will lead to the development of a new category of inhibi-
tors that goes beyond killing an individual parasite. The
inhibition of P. falciparum GCH1 might be able to pre-
vent drug resistance evolution of other drug-targetedfolate enzymes and could become a new strategy for
fighting the emerging threat of malaria drug resistance.
GCH1 is a well-conserved protein found in bacteria,
protozoa, plants and animals including human [26,27]. The
enzyme converts GTP into 7,8 dihydroneopterin triphos-
phate, the precursor of the pterin moiety in folate deriva-
tives (Figure 1) [26]. The enzyme forms a homodecameric
barrel-like structure with ten zinc-containing active sites
with each of them formed between three subunits [26]. The
enzyme catalyzes the breakages of the guanine and ribose
rings in GTP and rearranges them to form 7,8-dihydro-
neopterin triphosphate (Figure 1) [26,28]. The product was
further processed by subsequent enzymes in the pathway,
including DHPS and DHFR. In metazoa, GCH1 is con-
trolled by GTP cyclohydrolase I feedback regulatory protein
(GFRP) which acts as a negative regulator by binding to the
N-terminus of GCH1 [29,30]. This N-terminal extension
does not exist in the bacterial GCH1 proteins from Escheri-
chia coli and Thermus thermophilus.
With a series of the new findings on the significance
of P. falciparum GCH1, it is important to characterize
this enzyme from malaria parasites. Here the biochem-
ical properties of recombinant P. falciparum GCH1 were
reported. The roles of the key residues and domains
were tested by genetic complementation assays. A hom-
ology model was built to explore the overall structure
and conserved residues at the active site. The informa-
tion on the GCH1 enzyme could form a basis for the de-




A series of P. falciparum GCH1 truncations was con-
structed by PCR cloning from pET45b(+)/GCH1 with
Pfu DNA polymerase (Vivantis) and confirmed by direct
sequencing [19]. The genomic DNA samples from the
7G8 and RO-33 P. falciparum strains (a gift from Dr
Sarah Volkman, Harvard School of Public Health,
Boston, MA, USA) were used to construct N88Y and
R230K, respectively. H279S was made by QuikChange
II (Agilent Technologies) with the pET45b(+)/GCH1
template. Each corresponding clone was inserted into
pBAD33 with a ribosomal binding site.
Functional complementation assay
Functional complementation was performed in E. coli
K12 MG1655 ΔfolE (a gift from Professor Andrew
Hanson, University of Florida, Gainseville, FL, USA).
Construct was transformed by heat shock to E. coli K12
MG1655 ΔfolE with 300 μM thymidine supplement.
Growth analysis was performed with preculture in LB
broth (Bio Basic) supplemented with 300 μM thymidine
(Sigma-Aldrich), 30 μg ml-1 kanamycin (Bio Basic) and
Figure 1 GCH1 reaction in the folate pathway of Plasmodium
falciparum. Malaria parasites cannot salvage folate and need their
own de novo folate pathway to synthesize folate derivatives [24].
GCH1 converts GTP to 7,8-dihydroneopterin 3′-triphosphate, which
will become the pterin moiety of folate derivatives. Several P.
falciparum strains were found to contain multiple copies of gch1
(shown here as a large blue arrow). The next step in the folate
pathway of P. falciparum is driven by 6-pyruvoyltetrahydropterin
synthase (PTPS) to generate 6-hydroxymethyl-7,8 dihydroneopterin
(HMDHP). It is worth noting that bacteria need an extra
phosphorylase enzyme to remove the phosphate groups [25].
HMDHP is activated by the addition of two phosphate groups by
hydroxymethyl dihydropteridine pyrophosphokinase (HPPK).
Dihydropteroate synthase (DHPS) then combines the pterin moiety
with 4-aminobenzoate (pABA) to produce 7,8-dihydropteroate (DHP).
The last component to be added is glutamate via the reaction
driven by dihydrofolate synthase (DHFS) to form 7,8-dihydrofolate
(DHF). DHF is then reduced to 5,6,7,8-tetrahydrofolate (THF) by
dihydrofolate reductase (DHFR). Anti-malarial sulphadoxine (SDX)
and pyrimethamine (PYR) were combined to target two enzymes in
the folate pathway of malaria parasites. For the chemical detail of
the malarial folate pathway, see [2].
Kümpornsin et al. Malaria Journal 2014, 13:150 Page 3 of 11
http://www.malariajournal.com/content/13/1/15034 μg ml-1 chloramphenicol (Sigma-Aldrich). Starting
culture was grown in the same media with 0.02% ara-
binose (Calbiochem) and without thymidine supplement
at 37°C. Bacterial growth was determined using Spectro-
photometer (Shimadzu UV-2501PC) at two-hour inter-
vals. Each experiment was completed independently in
at least triplicate.Protein expression and enzymatic assay
Plasmodium falciparum Δ1-195 GCH1 or core GCH1 was
cloned into pET45b(+) and expressed in E. coli BL21(DE3)
RIL with 0.4 mM isopropyl β-D-1-thiogalactopyranoside at
37°C for two hours. Protein was purified by Ni2+-sepharose
(GE Healthcare) at 4°C in 50 mM NaH2PO4, 100 mM NaCl
and 20% glycerol, pH 8 with 20 mM, 70 mM and 300 mM
imidazole for binding, washing and elution, respectively.
The purified protein was dialyzed against 50 mM Tris–
HCl, 100 mM KCl and 20% glycerol, pH 7.8 at 4°C for
18 hours. The assay was performed according to a pub-
lished protocol with minor modification [31]. In short, the
complete reaction was composed of 50 mM Tris–HCl
pH 7.8, 100 mM KCl, 20% glycerol, 250 μM GTP and
2.5 μM recombinant P. falciparum GCH1. The reaction
was incubated in the dark at 37°C for 90 min and stopped
with 67 mM HCl. Non-fluorescent 7,8-dihydroneopterin
triphosphate was oxidized by 0.067% iodine (dissolved in
2% KI) to form fluorescent neopterin at room temperature
in the dark for one hour. 0.12% ascorbic acid and 55.6 mM
NaOH were then added. The product was measured by
SpectraMax M5 (Molecular Devices) with neopterin stand-
ard (Sigma). All experiments for obtaining kinetic parame-
ters were done in triplicate.
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Plasmodium falciparum GCH1 was submitted to SWISS-
MODEL homology modelling server [32]. A template
model was T. thermophilus GCH1 (PDB: 1WUR) which
served as a template for residue 203–383 of the conserved
core domain [28]. The homology model for P. falciparum
was obtained as a monomer. The decameric model was
constructed in PyMol by superimposition onto T. thermo-
philus GCH1. The decameric model was further refined by
optimizing side chain positions using Gromacs molecular
dynamic package and GROMOS 43A1 force field [33]. The
quality of the models was assessed by PROCHECK [34].
Secondary structure data were obtained from PDB acces-
sion number 1N3T, 1WUR, 1IS8 and 1FB1.
Results
Characteristics of Plasmodium falciparum GCH1
Plasmodium falciparum PFL1155w (PF3D7_1224000) was
shown to be malarial GTP cyclohydrolase I based on en-
zyme kinetics and complementation studies [19,35,36]. This
is consistent with the GCH1 activity previously identified
from parasite extract [37]. Plasmodium falciparum GCH1
was compared with the GCH1 sequences from the organ-
isms with known protein structures [28,38,39]. The well-
conserved core subunit of GCH1, which contains the active
site, is located at the C-terminus of P. falciparum GCH1
(Figure 2A). The analysis of the N-terminal sequences
showed a different picture with distinctively long unique se-
quences even among Plasmodium species (Figure 2A). The
unique N-terminal sequence might suggest a regulatory
mechanism unlike those GCH1 proteins from metazoan
which are regulated by GFRP via the N-terminal domain.
The homologue of GFRP has not been identified in Plasmo-
dium species.
Comparative analysis between P. falciparum GCH1
and the GCH1 sequences from the species with struc-
tural data was performed. The key residues for coordin-
ating with zinc are conserved with two cysteine and one
histidine residues (black circles, Figure 2B) [39]. The
fourth coordination with zinc was suggested to occur via
a water molecule [28]. The residues that are shown by
structural analysis to interact with GTP either via side
chain (black stars, Figure 2B) or backbone (white stars,
Figure 2B) are generally conserved. The homology
model of P. falciparum GCH1 showed consistency in
the overall structural component (Figure 2C). The N-
terminus of P. falciparum GCH1 was excluded from the
alignment and the model due to its uniqueness.
The homology model of P. falciparum GCH1 showed a
similar overall structure at the core part. The core compo-
nent of P. falciparum GCH1 was modelled and assembled
into homodecamer based on previous structural determin-
ation [28]. The core component of GCH1 belongs to the
T-fold protein family (T stands for tunnelling) [40]. Twopentameric rings are linked together by a clamp-like struc-
ture to form a face-to-face decameric barrel (Figure 2C).
The tunnel in the middle of the decamer is formed by the
last α-helix from every monomer. The active site is located
on the external side of the barrel with ten of them formed
between three subunits (the Homology model section for
detail).
Enzymatic properties of Plasmodium falciparum GCH1
In order to understand the biochemical properties of P.
falciparum GCH1, its kinetic parameters were deter-
mined. The core domain of GCH1 (residue 196–389)
from the 3D7 strain was chosen for this work because
the core GCH1 protein still retains enzymatic and com-
plementation activities. It is consistent with the fact that
the core domain of GCH1 was found to assemble into a
homodecameric structure with three subunits forming
one active site. The core enzyme was found to be soluble
and expressed well in bacteria compared to the full-
length version probably from the lack of the long repeti-
tive amino acid stretches at the N-terminus. The kinetic
assays for P. falciparum GCH1 were performed, and fits
of data gave Km of 12.06 μM and kcat of 0.039 s
-1. The
Km values of GCH1 are in the micromolar range
(4.2 μM and 31 μM for the GCH1 enzyme from T. ther-
mophilus and human respectively) similar to the binding
affinities of the SRP GTPase family [41]. It also means
that the concentration of cellular GTP (~200-600 μM)
exceeds the Km value of GCH1 [42].
The effects of temperature, salt and pH on the activity
of P. falciparum GCH1 were then studied. The enzyme
activity was found to be improved by the rise in
temperature even at 50°C (Figure 3A). The finding indi-
cates that feverish temperature in symptomatic malaria
patients would not interfere with the activity of P. falcip-
arum GCH1. High salt (1 M KCl) on the other hand
could diminish the activity of the enzyme (Figure 3B).
The best pH for the activity is at pH 9, but the activity
peak is relative high over the broad pH range with a sud-
den drop when the pH reaching 12 (Figure 3C).
The enzymatic reaction of GCH1 was initiated by the
attack of C8 of a guanine ring supposedly by a zinc-
activated water. The modification of C8 would interfere
with the enzymatic activity. 8-oxo-GTP was tested for its
inhibitory effect on P. falciparum GCH1. As expected,
8-oxo-GTP could inhibit the activity of P. falciparum
GCH1 with reduced fluorescent signal (Figure 3D). It
shifted the Vmax to 161.8 μM, but the value of km was
not changed indicating that 8-oxo-GTP acts as a com-
petitive inhibitor of GCH1. The overall enzymatic prop-
erties of GCH1 from the P. falciparum core domain and
from other organisms are in the same range, consistent
with the fact that the core GCH1 sequences are rela-
tively conserved.
Figure 2 (See legend on next page.)
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Figure 2 Comparison of the GCH1 protein from Plasmodium falciparum to GCH1 proteins with known structures. (A) Sequence alignment of the
GCH1 proteins. The GCH1 sequences were divided into the N-terminal regulatory domain and the C-terminal enzymatic core with the residue numbers on
each diagram. The homology scores compared to P. falciparum GCH1were shown as percent homology and colour shade (100% and black colour to its
own sequence). (B) Secondary structure diagram from known GCH1 structures and the homology model of P. falciparum GCH1 with α-helices in orange
and β-strands in blue. The secondary structure diagrams of the P. falciparum GCH1 model are at the top of the alignment. The conserved amino
acid residues are highlighted in black with labelled key residues (see text for detail). (C) Comparison of the overall homodecameric GCH1
structures. Two face-to-face pentameric rings are coloured in red and blue.
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complementation
A bacterial complementation assay was developed in order
to identify the components of GCH1 that are necessary for
its activity. The bacterial strains without gch1 (ΔfolE) was
used as a model for genetic complementation [43]. ΔfolE
requires thymidine supplement to survive. It was previously
shown that the expression of P. falciparum gch1 could
rescue the loss of bacterial gch1 allowing the growth in
the condition without thymidine supplement [19]. TheFigure 3 Factors affecting the activities of Plasmodium falciparum GC
the production of the oxidized neopterin product. (B) Effect of salt (KCl) on
falciparum GCH1. The pH values were varied from pH 5–13 with the data p
reaction in Figure 3A-3C was performed for 90 minutes. (D) Effect of 8-oxo
initial velocity was followed under various substrate concentrations.expression of wild-type P. falciparum GCH1 and mutant
proteins in ΔfolE bacteria was induced by arabinose. Wild-
type P. falciparum GCH1 can rescue the growth of ΔfolE
bacteria in the condition without thymidine. Histidine 279
in P. falciparum GCH1 is a key residue for the enzymatic
reaction (see below). The H279S mutant cannot rescue
ΔfolE bacteria, indicating that the enzymatic activity of P.
falciparum GCH1 is needed for genetic complementation
(Figure 4A). The natural genetic diversity in P. falciparum
gch1 beside copy number polymorphism was also analyzed.H1. (A) Effect of temperature shift on the GCH1 activity as shown by
the GCH1 activity. (C) Effect of pH change on the activity of P.
oint from pH 7.8, which was chosen for the enzymatic assay. Every
-GTP on the activity of P. falciparum GCH1. The inhibitory effect on
Figure 4 Genetic complementation of Plasmodium falciparum
GCH1 in bacteria. (A) Mutation effect on P. falciparum gch1
complementation. Wild-type P. falciparum GCH1 can rescue the loss
of a bacterial strain without its own gch1 (folE in bacteria). The loss
of functional P. falciparum GCH1 as in the H279S mutant abolishes
the complementation activity. Naturally-occurring mutations (N88Y
and R230K) were also tested for their genetic complementation
activities. (B) Effect of the N-terminal truncation on genetic
complementation. A series of the N-terminal truncates was made in
order to test their effect on genetic complementation. (C) Effect of
the C-terminal helix deletion on genetic complementation. The
well-conserved C-terminal helix was removed and tested for the
complementation activity by the mutant.
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identified and cloned from South American 7G8 and
African RO-33 P. falciparum strains, respectively. The mu-
tations were confirmed by direct sequencing and cloned
into inducible vectors. Both mutants can still rescue the
loss of bacterial gch1 in ΔfolE bacteria (Figure 4A), whichsuggests that these naturally occurring mutations do not
compromise basal enzymatic function.
The significance of the different domains in P. falcip-
arum GCH1 was studied starting with the N-terminal
domain. A series of the N-terminal truncates was made
and tested for their complementation activities. The de-
letions of the first 100 amino acid residues do not cause
any change in genetic complementation (Figure 4B).
Even the removal of the entire N-terminal domain does
not completely result in the loss of complementation
like in the case of H279S, but the deletion of the entire
N-terminal domain cannot reach the same level of com-
plementation observed with that of the wild-type
(Figure 4B).
Interestingly, two recent phosphoproteomic analyses in-
dependently identified protein phosphorylation at P. falcip-
arum GCH1 especially at the N-terminus of P. falciparum
GCH1 [44,45]. The control of GCH1 by protein phosphor-
ylation was reported in Drosophila melanogaster as a posi-
tive regulator for GCH1 [46]. The mutagenesis of the
phosphorylation sites in D. melanogaster GCH1 attenuated
the enzyme function [46]. In P. falciparum GCH1, the
phosphorylation sites were located at Ser109, Ser119 and
non-canonical Cys117 [44]. The deletion of this part (Δ1-
195) slightly compromised GCH1 complementation, but
no change was observed in the Δ1-50 and Δ1-100 trun-
cates. This observation does not exclude the importance of
the N-terminal domain on the function of P. falciparum
GCH1, but it suggests that the N-terminal part might play
a role in enzymatic control. The regulatory mechanism,
perhaps via phosphorylation, is not likely to affect bacterial
complementation assay used in this study. The unique N-
terminal sequence of P. falciparum GCH1 compared to
that of human indicates a different regulatory partner for
the malarial enzyme. It could be an alternative target for de-
veloping plasmodial GCH1 inhibitors without a significant
inhibitory effect on the human counterpart. The identifica-
tion of the putative GCH1 kinase in P. falciparum could re-
veal the role of protein phosphorylation on the regulation
of this enzyme.
The last helix of GCH1 that forms the lining of the
tunnel was also investigated. The tunnel at the centre of
the enzyme complex is common among the T-fold pro-
teins. Interestingly, the tunnel in GCH1 contains add-
itional α-helices from each monomer at the center of
the tunnel (Figure 2C). This conserved feature was
found in all GCH1 proteins from bacteria to metazoa.
Surprisingly, the deletion of this helix does not affect
genetic complementation at all (Figure 4C). This finding
suggests that the last helix is not directly required for
the catalytic activity of P. falciparum GCH1. Neverthe-
less, its high degree of conservation could imply the pos-
sibility of this helix to have another role such as in
enzyme regulation and protein complex assembly.
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The homology model of P. falciparum GCH1 was built
to observe the conserved residues with known functions
based on T. thermophilus GCH1. The key residues for
driving the enzymatic reactions and binding to the sub-
strate are well conserved as expected. The active site of
GCH1 is located at the interface between three subunits,
two from the same pentameric ring and the other one
from the opposite side. The X-ray structures of the
GCH1 proteins from human, E. coli and T. thermophilus
all suggested the presence of a metal ion bound to one
histidine and two cysteine residues at each active site.
The metal ion was found to be zinc by atomic absorp-
tion spectroscopy [39]. The zinc ion acts as Lewis base
activating the water molecule to form hydroxyl nucleo-
phile for nucleophilic attack at the guanine ring [38].
The residues in T. thermophilus GCH1 that coordinate
with zinc are His 111, Cys 108 and Cys 179 (Figure 5A),Figure 5 Comparison of the Plasmodium falciparum GCH1 homology
and (C) the structure of T. thermophilus GCH1 showing the active site. (B) a
views. See text for detail.which correspond to His 280, Cys 277 and Cys 348 in
the P. falciparum GCH1 homology model (Figure 5B).
Thermus thermophilus Glu 150 forms two hydrogen
bonds with N1 and N2 of the guanine ring. This inter-
action could exist in P. falciparum GCH1 via conserved
Glu 319. Another conserved chemical interaction is be-
tween the 2′ and 3′ hydroxyl groups of the ribose ring
and Ser 133 (Ser 302 in P. falciparum GCH1) (Figure 5A
and Figure 5B). Two His residues at the active site of T.
thermophilus GCH1 were shown to participate in the
catalytic reaction. Thermus thermophilus His177 (His
346 in P. falciparum GCH1) causes the protonation at
N-7 in the guanine ring, which promotes the cleavage of
N7/C8 at the guanine ring (Figures 5C and 5D) [28].
The replacement of the corresponding residue in E. coli
GCH1 (His 179 in E. coli) results in the loss of enzym-
atic activity [47]. The second His residue is T. thermo-
philus His 110 (His 279 in P. falciparum GCH1)model and the GCH1 structure from Thermus thermophilus. (A)
nd (D) The homology model of P. falciparum GCH1 with the same
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protonation of oxygen at the ribose moiety for the ribose
ring breakage [28]. It might also participate in the C8/
N9 imidazole ring cleavage to form formamidopyrimi-
dine [28]. The triphosphate moiety of GTP is recognized
by several basic residues located near the entrance of the
active site pocket (Figure 5C). The structure of T. ther-
mophilus GCH1 showed that Lys 134, Arg 137, Arg 183
and Arg 64 are responsible for the interactions with the
phosphate groups. They correspond to Lys 303, Arg 306,
Arg 352 and Arg 231 in the model of P. falciparum
GCH1, respectively (Figures 5C and 5D).
The homology model revealed strong conservation of the
key residues for substrate binding and conversion in P. fal-
ciparum indicating the strong selective pressure to
maintain the enzymatic activity. The H279S mutant was
constructed based on the homology model as a negative
control and found to lose both the enzymatic and comple-
mentation activities. Human and P. falciparum GCH1 pro-
teins are quite diverged especially at the residues lining the
active site and substrate binding pocket. The experimentally
solved structure of P. falciparum GCH1 is required to val-
idate the observation based on homology modelling.
Strategy for targeting Plasmodium falciparum GCH1
The enzymatic and complementation assays presented here
have potential to be developed further for testing GCH1 in-
hibitors. A substrate analogue was tested to validate the
capability of this assay to identify an inhibitor against plas-
modial GCH1. Plasmodium falciparum GCH1 is an at-
tractive drug target since it influences the course of drug
resistance evolution [19], and it appears to be vital for
erythrocytic-stage parasites as suggested by the failure to
make a gch1 knockout line in P. falciparum [1]. An inhibi-
tor specific to P. falciparum GCH1 could be combined with
antifolate inhibitors against DHFR and DHPS. The next-
generation anti-folates such as P218 have already shown
promising results in the assays with drug-resistant strains
and liver-stage parasites [11,48]. The compounds that can
effectively target liver-stage parasites with small side-effects
are in high demand for prophylactic and relapse treatments.
Nevertheless, cross-inhibition of putative plasmodial GCH1
inhibitors with human GCH1 needs to be avoided as well
since human GCH1 is an essential enzyme in the produc-
tion of tetrahydrobiopterin, a coenzyme in the production
of key neurotransmitters and nitric oxide [49].
The inhibition of P. falciparum GCH1 has the potential
to be a new strategy for drug resistance control especially
with the new antifolate compounds currently under devel-
opment [11,18,19]. Malaria drug resistance is a major obs-
tacle to malaria elimination especially with the parasites
from Southeast Asia, which are prone to develop drug re-
sistance and contain highly diverged genetic repertoires
[50,51]. Target inhibition of a factor contributing to drugresistance can be a novel strategy for overcoming malaria
drug resistance.
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